Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Association of uric acid levels before start of conditioning with mortality after alloSCT: a prospective, non-interventional study of the EBMT Transplant Complication Working Party.

Penack O, Peczynski C, van der Werf S, Finke J, Ganser A, Schoemans H, Pavlu J, Niittyvuopio R, Schroyens W, Kaynar L, Blau IW, van der Velden W, Sierra J, Cortelezzi A, Wulf G, Turlure P, Rovira M, Ozkurt Z, Pascual-Cascon MJ, Moreira MC, Clausen J, Greinix H, Duarte RF, Basak GW.

Haematologica. 2019 Oct 10. pii: haematol.2019.228668. doi: 10.3324/haematol.2019.228668. [Epub ahead of print]

2.

Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma.

Merz M, Hielscher T, Mai EK, Seckinger A, Hose D, Jauch A, Sauer S, Luntz S, Bertsch U, Raab MS, Neben K, Salwender H, Blau IW, Lindemann HW, Dürig J, Scheid C, Haenel M, Weisel K, Weber T, Delorme S, Goldschmidt H, Hillengass J.

Blood Cancer J. 2019 Aug 27;9(9):71. doi: 10.1038/s41408-019-0235-3. No abstract available.

3.

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.

Salwender H, Bertsch U, Weisel K, Duerig J, Kunz C, Benner A, Blau IW, Raab MS, Hillengass J, Hose D, Huhn S, Hundemer M, Andrulis M, Jauch A, Seidel-Glaetzer A, Lindemann HW, Hensel M, Fronhoffs S, Martens U, Hansen T, Wattad M, Graeven U, Munder M, Fenk R, Haenel M, Scheid C, Goldschmidt H.

BMC Cancer. 2019 May 28;19(1):504. doi: 10.1186/s12885-019-5600-x.

4.

Standardized assay for assessment of minimal residual disease in blood, bone marrow and apheresis from patients with plasma cell myeloma.

Blum A, Haussmann K, Streitz M, Schlickeiser S, Tietze-Buerger C, Blau IW, Uharek L.

Sci Rep. 2019 Feb 27;9(1):2922. doi: 10.1038/s41598-019-39631-2.

5.

Early differentiation of long-standing persistent atrial fibrillation using the characteristics of fibrillatory waves in surface ECG multi-leads.

Park J, Lee C, Leshem E, Blau I, Kim S, Lee JM, Hwang JA, Choi BI, Lee MH, Hwang HJ.

Sci Rep. 2019 Feb 26;9(1):2746. doi: 10.1038/s41598-019-38928-6.

6.

A new method for tracing the facial nerve trunk using the posterior auricular nerve.

Blau I, Vaisbuch Y, Marom A.

Clin Anat. 2019 Apr;32(3):453-457. doi: 10.1002/ca.23338. Epub 2019 Feb 5.

PMID:
30664254
7.

Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients.

Christen F, Hoyer K, Yoshida K, Hou HA, Waldhueter N, Heuser M, Hills RK, Chan W, Hablesreiter R, Blau O, Ochi Y, Klement P, Chou WC, Blau IW, Tang JL, Zemojtel T, Shiraishi Y, Shiozawa Y, Thol F, Ganser A, Löwenberg B, Linch DC, Bullinger L, Valk PJM, Tien HF, Gale RE, Ogawa S, Damm F.

Blood. 2019 Mar 7;133(10):1140-1151. doi: 10.1182/blood-2018-05-852822. Epub 2019 Jan 4.

PMID:
30610028
8.

Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation.

Frick M, Chan W, Arends CM, Hablesreiter R, Halik A, Heuser M, Michonneau D, Blau O, Hoyer K, Christen F, Galan-Sousa J, Noerenberg D, Wais V, Stadler M, Yoshida K, Schetelig J, Schuler E, Thol F, Clappier E, Christopeit M, Ayuk F, Bornhäuser M, Blau IW, Ogawa S, Zemojtel T, Gerbitz A, Wagner EM, Spriewald BM, Schrezenmeier H, Kuchenbauer F, Kobbe G, Wiesneth M, Koldehoff M, Socié G, Kroeger N, Bullinger L, Thiede C, Damm F.

J Clin Oncol. 2019 Feb 10;37(5):375-385. doi: 10.1200/JCO.2018.79.2184. Epub 2018 Nov 7.

PMID:
30403573
9.

[Pulmonary infiltrates in haematological patients].

Blau IW, Heinz WJ, Schwartz S, Lipp HP, Schafhausen P, Maschmeyer G.

MMW Fortschr Med. 2018 Jul;160(Suppl 4):12-17. doi: 10.1007/s15006-018-0727-2. Epub 2018 Jul 4. Review. German.

PMID:
29974434
10.

Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.

Mai EK, Hielscher T, Bertsch U, Schlenzka J, Salwender HJ, Munder M, Gerecke C, Dührsen U, Brossart P, Neben K, Hillengass J, Raab MS, Merz M, Baertsch MA, Jauch A, Hose D, Martin H, Lindemann HW, Blau IW, Scheid C, Weisel KC, Goldschmidt H; German-speaking Myeloma Multicenter Group (GMMG).

Leukemia. 2019 Jan;33(1):258-261. doi: 10.1038/s41375-018-0195-9. Epub 2018 Jun 29. No abstract available.

PMID:
29959413
11.

Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells.

Hammer Q, Rückert T, Borst EM, Dunst J, Haubner A, Durek P, Heinrich F, Gasparoni G, Babic M, Tomic A, Pietra G, Nienen M, Blau IW, Hofmann J, Na IK, Prinz I, Koenecke C, Hemmati P, Babel N, Arnold R, Walter J, Thurley K, Mashreghi MF, Messerle M, Romagnani C.

Nat Immunol. 2018 May;19(5):453-463. doi: 10.1038/s41590-018-0082-6. Epub 2018 Apr 9.

PMID:
29632329
12.

Single Nucleotide Polymorphisms in CD40L Predict Endothelial Complications and Mortality After Allogeneic Stem-Cell Transplantation.

Rachakonda SP, Dai H, Penack O, Blau O, Blau IW, Radujkovic A, Müller-Tidow C, Kumar R, Dreger P, Luft T.

J Clin Oncol. 2018 Mar 10;36(8):789-800. doi: 10.1200/JCO.2017.76.4662. Epub 2018 Jan 25.

PMID:
29369699
13.

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

Merz M, Jauch A, Hielscher T, Bochtler T, Schönland SO, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Hillengass J, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf IGH, Scheid C, Haenel M, Weisel KC, Goldschmidt H.

Blood Adv. 2017 Dec 27;2(1):1-9. doi: 10.1182/bloodadvances.2017013334. eCollection 2018 Jan 9.

14.

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

Merz M, Jauch A, Hielscher T, Bochtler T, Schönland SO, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Hillengass J, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf IGH, Scheid C, Haenel M, Weisel KC, Goldschmidt H.

Blood Adv. 2018 Jan 9;2(1):1-9. doi: 10.1182/bloodadvances.2017013334.

PMID:
31248901
15.

Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow Transplantation.

Rovó A, Kulasekararaj A, Medinger M, Chevallier P, Ribera JM, Peffault de Latour R, Knol C, Iacobelli S, Kanfer E, Bruno B, Maury S, Quarello P, Koh MBC, Schouten H, Blau IW, Tichelli A, Hill A, Risitano A, Passweg J, Marsh J, Dreger P, Dufour C; Severe Aplastic Anaemia Working Party of the EBMT.

Br J Haematol. 2019 Jan;184(2):294-298. doi: 10.1111/bjh.15074. Epub 2017 Dec 19. No abstract available.

PMID:
29265360
16.

Next-generation sequencing of patients with congenital anosmia.

Alkelai A, Olender T, Dode C, Shushan S, Tatarskyy P, Furman-Haran E, Boyko V, Gross-Isseroff R, Halvorsen M, Greenbaum L, Milgrom R, Yamada K, Haneishi A, Blau I, Lancet D.

Eur J Hum Genet. 2017 Dec;25(12):1377-1387. doi: 10.1038/s41431-017-0014-1. Epub 2017 Nov 13.

17.

Medical malpractice: An introduction for the dental practitioner.

Blau I, Levin L.

Quintessence Int. 2017;48(10):835-840. doi: 10.3290/j.qi.a39106. Review.

PMID:
29034379
18.

Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group.

Hoechstetter MA, Busch R, Eichhorst B, Bühler A, Winkler D, Eckart MJ, Vehling-Kaiser U, Schimke H, Jäger U, Hurtz HJ, Hopfinger G, Hartmann F, Fuss H, Abenhardt W, Blau I, Freier W, Müller L, Goebeler M, Wendtner CM, Bahlo J, Fischer K, Bentz M, Emmerich B, Döhner H, Hallek M, Stilgenbauer S.

Leukemia. 2017 Dec;31(12):2833-2837. doi: 10.1038/leu.2017.246. Epub 2017 Aug 14. No abstract available.

PMID:
28804126
19.

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

Goldschmidt H, Lokhorst HM, Mai EK, van der Holt B, Blau IW, Zweegman S, Weisel KC, Vellenga E, Pfreundschuh M, Kersten MJ, Scheid C, Croockewit S, Raymakers R, Hose D, Potamianou A, Jauch A, Hillengass J, Stevens-Kroef M, Raab MS, Broijl A, Lindemann HW, Bos GMJ, Brossart P, van Marwijk Kooy M, Ypma P, Duehrsen U, Schaafsma RM, Bertsch U, Hielscher T, Jarari L, Salwender HJ, Sonneveld P.

Leukemia. 2018 Feb;32(2):383-390. doi: 10.1038/leu.2017.211. Epub 2017 Jul 4.

PMID:
28761118
20.

Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.

Brissot E, Labopin M, Stelljes M, Ehninger G, Schwerdtfeger R, Finke J, Kolb HJ, Ganser A, Schäfer-Eckart K, Zander AR, Bunjes D, Mielke S, Bethge WA, Milpied N, Kalhs P, Blau IW, Kröger N, Vitek A, Gramatzki M, Holler E, Schmid C, Esteve J, Mohty M, Nagler A.

J Hematol Oncol. 2017 Jun 24;10(1):130. doi: 10.1186/s13045-017-0498-8.

21.

Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial.

Huhn S, Weinhold N, Nickel J, Pritsch M, Hielscher T, Hummel M, Bertsch U, Huegle-Doerr B, Vogel M, Angermund R, Hänel M, Salwender HJ, Weisel K, Dürig J, Görner M, Kirchner H, Peter N, Graeven U, Lordick F, Hoffmann M, Reimer P, Blau IW, Jauch A, Dembowsky K, Möhler T, Wuchter P, Goldschmidt H.

Bone Marrow Transplant. 2017 Aug;52(8):1194-1198. doi: 10.1038/bmt.2017.91. Epub 2017 May 15. No abstract available.

22.

Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation.

Merz M, Jauch A, Hielscher T, Mai EK, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf I, Scheid C, Haenel M, Weisel K, Goldschmidt H, Hillengass J.

Haematologica. 2017 Aug;102(8):1432-1438. doi: 10.3324/haematol.2017.168005. Epub 2017 May 11.

23.

Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.

Schlenk RF, Stegelmann F, Reiter A, Jost E, Gattermann N, Hebart H, Waller C, Hochhaus A, Platzbecker U, Schafhausen P, Blau IW, Verbeek W, Heidel FH, Werner M, Kreipe H, Teleanu V, Benner A, Döhner H, Grießhammer M, Döhner K.

Leukemia. 2017 Apr;31(4):889-895. doi: 10.1038/leu.2016.299. Epub 2016 Oct 24.

PMID:
27774990
24.

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.

Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Hillengass J, Raab MS, Schurich B, Munder M, Brossart P, Gerecke C, Lindemann HW, Zeis M, Weisel K, Duerig J, Goldschmidt H.

Haematologica. 2016 Dec;101(12):e485-e487. Epub 2016 Aug 18. No abstract available.

25.

Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial.

Schmitt M, Hückelhoven AG, Hundemer M, Schmitt A, Lipp S, Emde M, Salwender H, Hänel M, Weisel K, Bertsch U, Dürig J, Ho AD, Blau IW, Goldschmidt H, Seckinger A, Hose D.

Oncotarget. 2016 Aug 11;8(49):84847-84862. doi: 10.18632/oncotarget.11215. eCollection 2017 Oct 17.

26.

Prophylactic immunoglobulin therapy in secondary immune deficiency - an expert opinion.

Agostini C, Blau IW, Kimby E, Plesner T.

Expert Rev Clin Immunol. 2016 Sep;12(9):921-6. doi: 10.1080/1744666X.2016.1208085. Epub 2016 Jul 14. Review.

PMID:
27415820
27.

Facilitated subcutaneous immunoglobulin administration (fSCIg): a new treatment option for patients with secondary immune deficiencies.

Blau IW, Conlon N, Petermann R, Nikolov N, Plesner T.

Expert Rev Clin Immunol. 2016 Jul;12(7):705-11. doi: 10.1080/1744666X.2016.1183482. Epub 2016 May 13.

PMID:
27156362
28.

Lichtheimia Infection in a Lymphoma Patient: Case Report and a Brief Review of the Available Diagnostic Tools.

Zimmerli S, Bialek R, Blau IW, Christe A, Lass-Flörl C, Presterl E.

Mycopathologia. 2016 Aug;181(7-8):561-6. doi: 10.1007/s11046-016-0010-y. Epub 2016 Apr 26. Review.

PMID:
27115610
29.

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.

Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Kirito K, Besses C, Hino M, Moiraghi B, Miller CB, Cazzola M, Rosti V, Blau I, Mesa R, Jones MM, Zhen H, Li J, Francillard N, Habr D, Kiladjian JJ.

Haematologica. 2016 Jul;101(7):821-9. doi: 10.3324/haematol.2016.143644. Epub 2016 Apr 21.

30.

A role for TENM1 mutations in congenital general anosmia.

Alkelai A, Olender T, Haffner-Krausz R, Tsoory MM, Boyko V, Tatarskyy P, Gross-Isseroff R, Milgrom R, Shushan S, Blau I, Cohn E, Beeri R, Levy-Lahad E, Pras E, Lancet D.

Clin Genet. 2016 Sep;90(3):211-9. doi: 10.1111/cge.12782. Epub 2016 May 31.

PMID:
27040985
31.

Multiple myeloma cells modify VEGF/IL-6 levels and osteogenic potential of bone marrow stromal cells via Notch/miR-223.

Berenstein R, Nogai A, Waechter M, Blau O, Kuehnel A, Schmidt-Hieber M, Kunitz A, Pezzutto A, Dörken B, Blau IW.

Mol Carcinog. 2016 Dec;55(12):1927-1939. doi: 10.1002/mc.22440. Epub 2015 Nov 24.

PMID:
27023728
32.

Anti-Aspergillus immunoglobulin-G testing in serum of hematopoietic stem cell transplant recipients.

Erdmann JH, Graf B, Blau IW, Fischer F, Timm G, Hemmati P, Arnold R, Penack O.

Transpl Infect Dis. 2016 Jun;18(3):354-60. doi: 10.1111/tid.12529. Epub 2016 May 17.

PMID:
26998687
33.

Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma.

Weinhold N, Kirn D, Seckinger A, Hielscher T, Granzow M, Bertsch U, Egerer G, Salwender H, Blau IW, Weisel K, Hillengass J, Raab MS, Hose D, Goldschmidt H, Jauch A.

Haematologica. 2016 Mar;101(3):e116-9. doi: 10.3324/haematol.2015.136929. Epub 2015 Nov 26. No abstract available.

34.

Tyrosine Kinases in Cancer.

Blau O, Afanasyev B, Blau IW.

Biomark Insights. 2015 Nov 2;10(Suppl 3):41-2. doi: 10.4137/BMI.S34403. eCollection 2015. No abstract available.

35.

Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse.

Garg M, Nagata Y, Kanojia D, Mayakonda A, Yoshida K, Haridas Keloth S, Zang ZJ, Okuno Y, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ding LW, Alpermann T, Sun QY, Lin DC, Chien W, Madan V, Liu LZ, Tan KT, Sampath A, Venkatesan S, Inokuchi K, Wakita S, Yamaguchi H, Chng WJ, Kham SK, Yeoh AE, Sanada M, Schiller J, Kreuzer KA, Kornblau SM, Kantarjian HM, Haferlach T, Lill M, Kuo MC, Shih LY, Blau IW, Blau O, Yang H, Ogawa S, Koeffler HP.

Blood. 2015 Nov 26;126(22):2491-501. doi: 10.1182/blood-2015-05-646240. Epub 2015 Oct 5.

36.

Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia.

Berenstein R, Blau IW, Suckert N, Baldus C, Pezzutto A, Dörken B, Blau O.

J Exp Clin Cancer Res. 2015 May 22;34:55. doi: 10.1186/s13046-015-0173-2.

37.

Multiple myeloma cells alter the senescence phenotype of bone marrow mesenchymal stromal cells under participation of the DLK1-DIO3 genomic region.

Berenstein R, Blau O, Nogai A, Waechter M, Slonova E, Schmidt-Hieber M, Kunitz A, Pezzutto A, Doerken B, Blau IW.

BMC Cancer. 2015 Feb 18;15:68. doi: 10.1186/s12885-015-1078-3.

38.

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.

Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Hillengass J, Raab MS, Schurich B, Munder M, Schmidt-Wolf IG, Gerecke C, Lindemann HW, Zeis M, Weisel K, Duerig J, Goldschmidt H.

Haematologica. 2015 Jul;100(7):964-9. doi: 10.3324/haematol.2015.124347. Epub 2015 Apr 3.

39.

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.

Mai EK, Bertsch U, Dürig J, Kunz C, Haenel M, Blau IW, Munder M, Jauch A, Schurich B, Hielscher T, Merz M, Huegle-Doerr B, Seckinger A, Hose D, Hillengass J, Raab MS, Neben K, Lindemann HW, Zeis M, Gerecke C, Schmidt-Wolf IG, Weisel K, Scheid C, Salwender H, Goldschmidt H.

Leukemia. 2015 Aug;29(8):1721-9. doi: 10.1038/leu.2015.80. Epub 2015 Mar 19.

PMID:
25787915
40.

Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy.

Blau O, Blau IW.

Stem Cells Cloning. 2014 Dec 4;7:101-8. doi: 10.2147/SCCAA.S50514. eCollection 2014. Review.

41.

Single-Nucleotide Polymorphisms Within the Thrombomodulin Gene (THBD) Predict Mortality in Patients With Graft-Versus-Host Disease.

Rachakonda SP, Penack O, Dietrich S, Blau O, Blau IW, Radujkovic A, Isermann B, Ho AD, Uharek L, Dreger P, Kumar R, Luft T.

J Clin Oncol. 2014 Oct 20;32(30):3421-7. doi: 10.1200/JCO.2013.54.4056. Epub 2014 Sep 15.

PMID:
25225421
42.

Association between low uric acid levels and acute graft-versus-host disease.

Ostendorf BN, Blau O, Uharek L, Blau IW, Penack O.

Ann Hematol. 2015 Jan;94(1):139-44. doi: 10.1007/s00277-014-2180-3. Epub 2014 Aug 31.

PMID:
25172456
43.

Efficacy and pharmacologic data of second-generation tyrosine kinase inhibitor nilotinib in BCR-ABL-positive leukemia patients with central nervous system relapse after allogeneic stem cell transplantation.

Reinwald M, Schleyer E, Kiewe P, Blau IW, Burmeister T, Pursche S, Neumann M, Notter M, Thiel E, Hofmann WK, Kolb HJ, Burdach S, Bender HU.

Biomed Res Int. 2014;2014:637059. doi: 10.1155/2014/637059. Epub 2014 Jun 15.

44.

Synchronous tuberculosis, Epstein-Barr virus-associated lymphoproliferative disorder and cytomegalovirus infection in an allogeneic transplant recipient: a case report.

Ostendorf BN, Jehn CF, Vuong LG, Nogai H, Hemmati PG, Gebauer B, Penack O, Blau IW, Anagnostopoulos I, Arnold R.

Springerplus. 2014 Jun 2;3:278. doi: 10.1186/2193-1801-3-278. eCollection 2014.

45.

Malarial anemia: digestive vacuole of Plasmodium falciparum mediates complement deposition on bystander cells to provoke hemophagocytosis.

Dasari P, Fries A, Heber SD, Salama A, Blau IW, Lingelbach K, Bhakdi SC, Udomsangpetch R, Torzewski M, Reiss K, Bhakdi S.

Med Microbiol Immunol. 2014 Dec;203(6):383-93. doi: 10.1007/s00430-014-0347-0. Epub 2014 Jul 2.

PMID:
24985035
46.

Comparative examination of various PCR-based methods for DNMT3A and IDH1/2 mutations identification in acute myeloid leukemia.

Berenstein R, Blau IW, Kar A, Cay R, Sindram A, Seide C, Blau O.

J Exp Clin Cancer Res. 2014 May 21;33:44. doi: 10.1186/1756-9966-33-44.

47.

Rabbit antithymocyte globulin induces rapid expansion of effector memory CD8 T cells without accelerating acute graft versus host disease.

Wittenbecher F, Rieger K, Dziubianau M, Herholz A, Mensen A, Blau IW, Uharek L, Dörken B, Thiel A, Na IK.

Leuk Res Rep. 2013 Sep 27;2(2):82-5. doi: 10.1016/j.lrr.2013.09.001. eCollection 2013.

48.

A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course.

Rizzieri D, Vey N, Thomas X, Huguet-Rigal F, Schlenk RF, Krauter J, Kindler T, Gjertsen BT, Blau IW, Jacobsen TF, Johansen M, Bergeland T, Gianella-Borradori A, Krug U.

Leuk Lymphoma. 2014 Sep;55(9):2114-9. doi: 10.3109/10428194.2013.867489. Epub 2014 Jan 24.

PMID:
24255981
49.

CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT.

Schmidt-Hieber M, Labopin M, Beelen D, Volin L, Ehninger G, Finke J, Socié G, Schwerdtfeger R, Kröger N, Ganser A, Niederwieser D, Polge E, Blau IW, Mohty M.

Blood. 2013 Nov 7;122(19):3359-64. doi: 10.1182/blood-2013-05-499830. Epub 2013 Sep 13.

PMID:
24037724
50.

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.

Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Blau IW, Vellenga E, Weisel K, Pfreundschuh M, Jie KS, Neben K, van de Velde H, Duehrsen U, Schaafsma MR, Lindemann W, Kersten MJ, Peter N, Hänel M, Croockewit S, Martin H, Wittebol S, Bos GM, van Marwijk-Kooy M, Wijermans P, Goldschmidt H, Lokhorst HM.

Haematologica. 2014 Jan;99(1):148-54. doi: 10.3324/haematol.2013.087585. Epub 2013 Aug 30.

Supplemental Content

Support Center